1145PApatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma

ConclusionsApatinib achieved excellent disease control in platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma. More attention needs to be paid to toxicity management.Legal entity responsible for the studyJiangsu Hengrui Pharmaceutical Co., Ltd.FundingJiangsu Hengrui Pharmaceutical Co., Ltd.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research